Redefining bioseparations science with MaxPeak Premier Solutions

Overview

Due to the increased pressure requirements of running UHPLC, most systems are comprised of a combination of metals, including stainless steel, MP35N (a nickel-cobalt alloy) and titanium. While these materials offer many benefits, there are drawbacks to having any form of metal in the flowpath. It is well known, for example, that many biopharmaceutical compounds, such as oligonucleotides, phosphopeptides and acidic peptides, can have undesirable interactions with metal-containing chromatographic surfaces.

In this webinar, scientists Jennifer Simeone and Jacob Kellett, from Waters Corporation, will describe how MaxPeak Premier Solutions reduce metal-analyte interactions to improve the reproducibility, recovery, and overall peak shape in biopharmaceutical-based assays.

Key learning objectives:

• Differentiate biocompatible LCs versus inert LCs, which do not exhibit non-specific binding due to interactions between analytes and metal-containing surfaces
• Learn techniques to assess system inertness prior to analysis of biopharmaceutical compounds
• Learn how the performance, sensitivity, and reproducibility of peptide mapping can be negatively affected by metal interactions
• Explore the advantages of MaxPeak High Performance Surfaces technology for LC hardware that can mitigate metal interactions and improve reproducibility, recovery, and peak shape

Who should attend:

• Lab directors, managers, and analytical scientists who are involved in biopharmaceutical or antisense therapy development, manufacturing, and/or QC
• Lab managers or scientists that require better reproducibility for gradient separations at low flow
• Bioanalytical scientists performing quantitative studies and seeking to improve detection limits or sensitivity